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DNA- Deoxyribonucleic acid 







Et2O- Diethyl ether 
EtOAc- Ethyl acetate 
FabI- Enoyl-acyl-carrier protein reductase 
FabH- β-ketoacyl-acyl-carrier protein synthase 
G6PD- Glucose-6-phosphate dehydrogenase 
HBTU- 2-(1H-benzotriazol-1-ly)-1,1,3,3-tetramethyluronium 
HPMA- N-(2-hydroxypropyl)metacrylate polymers 
MBA- Methylenebisacrylamide 
MRP- Multiple resistance associated proteins 
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RNA- Ribonucleic acid 
TEA- Triethylamine 
TRIS- Tris(2-aminoethyl)amine 
























4-Aminoquinolines have a long and successful history as antimalarials as they have 
provided a number of useful antimalarials. P. falciparum, a causative organism of the 
most deadly form of human malaria, is generally slow to develop resistance to these 
drugs. 4-Aminoquinoline derivatives appear to bind to nucleoproteins and interfere with 
protein synthesis in susceptible organisms; the drugs intercalate readily into double-
stranded DNA and inhibit both DNA and RNA polymerase. In addition, 4-
aminoquinolines are found to concentrate in parasites’ digestive vacuoles, thereby 
increasing the pH of the vacuoles, and thus interfere with the parasites’ ability to 
metabolize. 4-Aminoquinolines on the other hand have raised considerable interest 
because of their anti-carcinogenic properties and their ability to inhibit tumor 
development and presently are being used in combination therapy with anti-cancer drugs 
to inhibit development of drug resistance in cancer cells caused by anti-cancer drugs. 8-
Aminoquinoline mechanism is quite different from that of 4-aminoquinoline in that the 8-
aminoquinolines are converted in the liver to an active quinone metabolite creating 
oxygen free radicals that interfere with the plasmodial electron chain transport chain 
during respiration.   
 
Anti-cancer drugs are often toxic when delivered straight, but the bioreversible drug 
conjugation of anticancer drugs to water-soluble macromolecular carriers has proved to 
enhance the therapeutic effectiveness of anticancer drugs. Following facilitated 
pharmacokinetics pathways, the conjugates, acting as prodrugs, will release the active 
drug species in the transformed target cells and their designs are geared towards reducing 
pharmacological barriers of toxicity, drug resistance and poor bioavailability encountered 
with currently used anti-cancer drugs. In order to demonstrate the multidrug binding 
capacity of polyaspartamide, the co-conjugation of 4- and 8-aminoquinoline derivatives 




This present project aimed at the anchoring of 4-aminoquinoline to various amine 
functionalized polymeric carriers, and selected macromolecular 4-aminoquinoline 
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